Aurora Therapeutics winds down lead gene-editing program after layoffs
Aurora Therapeutics, which pioneered bespoke CRISPR-based treatments, has cut staff and halted its primary clinical program. The company had been applying base editing to correct specific genetic mutations. Its future now appears uncertain as it steps back from its core focus.
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapies.” Browse more stories.